Clinical trials: CCSVI
Multiple Sclerosis, Relapsing-Remitting
A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS
STUDY OBJECTIVES: Primary Objective: Assessment of treatment safety based on incidence of any treatment emergent/treatment associated adverse events prior to discharge and at 1, 3, 6 and 12 months post treatment.
- Trial name
- NCT02418325
- Testing
- Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells, Liberation therapy
- Where
- Trinidad and Tobago
- Volunteers
- 69 people
- Sponsor
- Genesis Limited
Multiple Sclerosis, Relapsing-Remitting
A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS
STUDY OBJECTIVES: Primary Objective: Assessment of treatment safety based on incidence of any treatment emergent/treatment associated adverse events prior to discharge and at 1, 3, 6 and 12 months post treatment.
- Trial name
- NCT02587715
- Testing
- Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells, Liberation therapy
- Where
- Trinidad and Tobago
- Volunteers
- 69 people
- Sponsor
- Novo Cellular Medicine Institute LLP
Multiple Sclerosis, Relapsing-Remitting
A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS
STUDY OBJECTIVES: Primary Objective: Assessment of treatment safety based on incidence of any treatment emergent/treatment associated adverse events prior to discharge and at 1, 3, 6 and 12 months post treatment.
- Trial name
- NCT02587806
- Testing
- Autologous Bone Marrow-Derived Mononuclear Stem Cells, Liberation therapy
- Where
- 2 sites in India, Trinidad and Tobago
- Volunteers
- 69 people
- Sponsor
- Novo Cellular Medicine Institute LLP
Venous Irregularities, Flow and Perfusion in MS and Non-MS Participants
Venous Irregularities, Flow and Perfusion in MS Study
1. What is the true incidence of CCSVI in patients with MS in a study comparing MRI on MS patients and controls. 2. Are the beneficial outcomes from treatment placebo? By measuring changes in brain perfusion and Cerebrospinal…
- Trial name
- VERIFYMS (NCT01593904)
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Synergy Health Concepts, Inc.
To Determine the Safety and Validity of Venous Angioplasty and, Valvuloplasty in the Treatment of CCSVI. In Addition, it Will
Radiographic and Intravascular (IVUS) Evaluation of Venous Morphology During CCSVI Treatment
Radio graphic and Intravascular (IVUS) Evaluation of Venous Morphology During Chronic Cerebral Spinal Venous Insufficiency Treatment
- Conditions
- To Determine the Safety and Validity of Venous Angioplasty and, Valvuloplasty in the Treatment of CCSVI. In Addition, it Will, Allow Researchers to Sub-classify Valve Morphology in Relation, to Treatment Success. This Will be Evidenced by Venous Patency
- Trial name
- Resrch_Reg_2 (NCT01593891)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Synergy Health Concepts, Inc.
Chronic Cerebral Spinal Venous Insufficiency
Venous Obstruction in Neurodegenerative Disorders Research Registry
To establish if there are venous obstructions in patients with neurodegenerative disorders
- Trial name
- NCT01593358
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Synergy Health Concepts, Inc.